FDA Issues Draft Guidance on Developing HIV Prevention Drugs

Drug Industry Daily
Clinical trials for HIV prevention drugs should generally involve two well-controlled trials, but a single Phase III trial can suffice if the results are supported by additional evidence, the FDA said in a new draft guidance.

To View This Article:


Subscribe To Drug Industry Daily